FDA approves Cingulate's Ctx-1301?
Market price history
Rolling 7-day window of market NO price with the OU fair-price range overlay.
Not enough history yet for a chart.
New points land on each refresh — check back shortly.
New points land on each refresh — check back shortly.
Market price
YES32¢ (32%)
NO68¢ (68%)
Latest refresh · prices in cents
Polymarket • Volume: $6.7K • Updated 16m agoCloses: 2026-05-31 (6d)
Polymarket · Companies
OU's Pick
YES at 32¢ · pays 3.2×
Price gap
Polymarket32¢
→OU's fair45¢
+13¢ underpriced · pays 3.2×
Confidence
Moderate
Cingulate reported positive Phase 3 safety and efficacy data for CTx-1301 and remains on track for a mid-2025 NDA submission which aligns with a May 2026 PDUFA date.
Wide edge+13¢
Closes in6d 1h
Off market consensus
Affiliate link — we may earn a commission. Not financial advice. For informational purposes only. Prediction markets involve risk of loss. AI may contain errors.